Topiramate and Dactinomycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Topiramate and Dactinomycin. Common interactions include renal tubular acidosis among males.

The phase IV clinical study analyzes what interactions people who take Topiramate and Dactinomycin have. It is created by eHealthMe based on reports of 7 people who take Topiramate and Dactinomycin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 18, 2023

7 people who take Topiramate and Dactinomycin together, and have interactions are studied.


What is Topiramate?

Topiramate has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 45,728 Topiramate users for its effectiveness, alternative drugs and more.

What is Dactinomycin?

Dactinomycin has active ingredients of dactinomycin. eHealthMe is studying from 2,273 Dactinomycin users for its effectiveness, alternative drugs and more.

Number of Topiramate and Dactinomycin reports submitted per year:

Topiramate and Dactinomycin drug interactions.

Common Topiramate and Dactinomycin drug interactions by gender *:

female:

n/a

male:

  1. Renal tubular acidosis
  2. Tubulointerstitial nephritis
  3. Enteritis
  4. Neuralgia
  5. Pancreatitis
  6. Neoplasm malignant
  7. Ewing's sarcoma recurrent
  8. Hypertension
  9. Radiation injury

Common Topiramate and Dactinomycin drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Renal tubular acidosis
  2. Tubulointerstitial nephritis
  3. Enteritis
  4. Neuralgia
  5. Pancreatitis
  6. Neoplasm malignant
  7. Ewing's sarcoma recurrent
  8. Hypertension
  9. Radiation injury

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Topiramate and Dactinomycin?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Topiramate and Dactinomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Topiramate side effects:

Browse all side effects of Topiramate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Dactinomycin side effects:

Browse all side effects of Dactinomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Topiramate interactions:

Browse all interactions between Topiramate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Dactinomycin interactions:

Browse all interactions between Dactinomycin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on topiramate and dactinomycin (the active ingredients of Topiramate and Dactinomycin, respectively), and Topiramate and Dactinomycin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Topiramate and Dactinomycin.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: